Search Results - "Westwood, John‐Paul"

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura by Peyvandi, Flora, Scully, Marie, Kremer Hovinga, Johanna A, Cataland, Spero, Knöbl, Paul, Wu, Haifeng, Artoni, Andrea, Westwood, John-Paul, Mansouri Taleghani, Magnus, Jilma, Bernd, Callewaert, Filip, Ulrichts, Hans, Duby, Christian, Tersago, Dominique

“…Thrombotic thrombocytopenic purpura is often caused by an autoantibody to ADAMTS13, resulting in ultralarge von Willebrand factor, which induces platelet…”
Get full text

Real‐world, single‐center experience of SARS‐CoV‐2 vaccination in immune thrombocytopenia by Woolley, Philippa, Tailor, Anish, Shah, Raakhee, Westwood, John‐Paul, Scully, Marie

“…Background Immune thrombocytopenic purpura (ITP) relapse following vaccination remains poorly reported in the adult population. Objectives This report details…”
Get full text

The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura by Doyle, Andrew J., Stubbs, Matthew J., Lester, Will, Thomas, Will, Westwood, John‐Paul, Thomas, Mari, Percy, Charles, Prasannan, Nithya, Scully, Marie

“…Summary Rituximab, an anti‐CD20 monoclonal antibody, can be used to treat immune thrombotic thrombocytopenic purpura (iTTP) during acute presentation or…”
Get full text

Rituximab‐induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: the role of anti‐rituximab antibodies by Vendramin, Chiara, Thomas, Mari, Westwood, John‐Paul, McGuckin, Siobhan, Scully, Marie

Get full text

Redefining outcomes in immune TTP: an international working group consensus report by Cuker, Adam, Cataland, Spero R., Coppo, Paul, de la Rubia, Javier, Friedman, Kenneth D., George, James N., Knoebl, Paul N., Kremer Hovinga, Johanna A., Lӓmmle, Bernhard, Matsumoto, Masanori, Pavenski, Katerina, Peyvandi, Flora, Sakai, Kazuya, Sarode, Ravi, Thomas, Mari R., Tomiyama, Yoshiaki, Veyradier, Agnès, Westwood, John-Paul, Scully, Marie

“…Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal thrombotic microangiopathy caused by autoantibody-mediated severe deficiency…”
Get full text

Characterization and treatment of congenital thrombotic thrombocytopenic purpura by Alwan, Ferras, Vendramin, Chiara, Liesner, Ri, Clark, Amanda, Lester, William, Dutt, Tina, Thomas, William, Gooding, Richard, Biss, Tina, Watson, H.G., Cooper, Nichola, Rayment, Rachel, Cranfield, Tanya, van Veen, Joost J., Hill, Quentin A., Davis, Sarah, Motwani, Jayashree, Bhatnagar, Neha, Priddee, Nicole, David, Marianna, Crowley, Maeve P., Alamelu, Jayanthi, Lyall, Hamish, Westwood, John-Paul, Thomas, Mari, Scully, Marie

“…Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra-rare thrombomicroangiopathy caused by an inherited deficiency of a disintegrin and…”
Get full text

The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry by Hassan, Sevda, Westwood, John‐Paul, Ellis, Debra, Laing, Chris, Mc Guckin, Siobhan, Benjamin, Sylvia, Scully, Marie

“…Summary Thrombotic microangiopathies (TMAs) are frequently difficult to differentiate clinically, and measurement of ADAMTS13 (a disintegrin and…”
Get full text

Acquired Glanzmann's thrombasthenia with IgG and IgA against activated αIIbβ3 by Adela Constantinescu‐Bercu, McCann, Sabina, Hmaid, Amjad, de Groot, Rens, Singh, Deepak, Gohil, Satyen H, Thomas, Mari, Scully, Marie, John‐Paul Westwood

Get full text

Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy by Doyle, Andrew J., Stubbs, Matthew J., Dutt, Tina, Lester, Will, Thomas, Will, van Veen, Joost, Hermans, Joannes, Cranfield, Tanya, Hill, Quentin A., Clark, Amanda, Bagot, Catherine, Austin, Steven, Westwood, John-Paul, Thomas, Mari, Scully, Marie

“…•Forty percent of patients with iTTP relapse after 5 years of follow-up.•Preemptive anti-CD20 therapy is efficacious in 96% of ADAMTS13 relapses regardless of…”
Get full text

A single‐center prospective study on the safety of plasma exchange procedures using a double‐viral‐inactivated and prion‐reduced solvent/detergent fresh‐frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy by Vendramin, Chiara, McGuckin, Siobhan, Alwan, Ferras, Westwood, John‐Paul, Thomas, Mari, Scully, Marie

“…BACKGROUND Patients presenting with acute episodes of thrombotic microangiopathies (TMAs) require urgent access to plasma exchange (PEX). OctaplasLG, a…”
Get full text

Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura by Westwood, John‐Paul, Langley, Kathryn, Heelas, Edward, Machin, Samuel J., Scully, Marie

“…Summary Complement dysregulation is key in the pathogenesis of atypical Haemolytic Uraemic Syndrome (aHUS), but no clear role for complement has been…”
Get full text

Immune thrombocytopenia in adults: A single‐centre review of demographics, clinical features and treatment outcomes by Woolley, Philippa, Newton, Rosalind, Mc Guckin, Siobhan, Thomas, Mari, Westwood, John‐Paul, Scully, Marie A.

“…Objectives Primary immune thrombocytopenia (ITP) is a bleeding disorder characterised by an isolated thrombocytopenia in the absence of an alternative…”
Get full text

Pharmacological venous thromboembolism prophylaxis in elective cranial surgery: a systematic review of time of initiation, regimen and duration by Tan, Ian, Pandit, Anand S., Joshi, Shivani, Khan, Mehdi, Sayar, Zara, Westwood, John-Paul, Cohen, Hannah, Toma, Ahmed K.

“…Pharmacological prophylaxis of venous thromboembolism (VTE) requires nuanced decision-making to balance the risk of VTE against haemorrhage. This problem is…”
Get full text

Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens by Westwood, John-Paul, Thomas, Mari, Alwan, Ferras, McDonald, Vickie, Benjamin, Sylvia, Lester, William A., Lowe, Gillian C., Dutt, Tina, Hill, Quentin A., Scully, Marie

“…Acute antibody-mediated thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy with high morbidity and mortality. Rituximab is highly…”
Get full text

Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era by Prasannan, Nithya, Thomas, Mari, Stubbs, Matthew, Westwood, John-Paul, de Groot, Rens, Singh, Deepak, Scully, Marie

“…•Twenty-eight percent of patients treated with caplacizumab had persistent ADAMTS13 activity <30% within 30 + 28 days after PEX.•In patients with ADAMTS13…”
Get full text

Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura by Alwan, Ferras, Vendramin, Chiara, Vanhoorelbeke, Karen, Langley, Katy, McDonald, Vickie, Austin, Steve, Clark, Amanda, Lester, William, Gooding, Richard, Biss, Tina, Dutt, Tina, Cooper, Nichola, Chapman, Oliver, Cranfield, Tanya, Douglas, Kenny, Watson, H.G., van Veen, J.J., Sibson, Keith, Thomas, William, Manson, Lynn, Hill, Quentin A., Benjamin, Sylvia, Ellis, Debra, Westwood, John-Paul, Thomas, Mari, Scully, Marie

“…Immune-mediated thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder caused by antibodies against ADAMTS13. From the United Kingdom TTP…”
Get full text

The role of complement activation in COPD exacerbation recovery by Westwood, John-Paul, Mackay, Alexander J, Donaldson, Gavin, Machin, Samuel J, Wedzicha, Jadwiga A, Scully, Marie

“…http://ow.ly/ZaPj303xxPf…”
Get full text

Acquired Glanzmann's thrombasthenia with IgG and IgA against activated α IIb β 3 by Constantinescu-Bercu, Adela, McCann, Sabina, Hmaid, Amjad, de Groot, Rens, Singh, Deepak, Gohil, Satyen H, Thomas, Mari, Scully, Marie, Westwood, John-Paul

Get full text

Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase by Westwood, John Paul, Scully, Marie

“…Modern therapy for acute TTP has resulted in a dramatic improvement in outcomes, with the combination of plasma exchange, immunosuppression, and caplacizumab…”
Get full text

IVIg-exposure and thromboembolic event risk: findings from the UK Biobank by Kapoor, Mahima, Hunt, Ian, Spillane, Jennifer, Bonnett, Laura Jayne, Hutton, Elspeth Jane, McFadyen, James, Westwood, John-Paul, Lunn, Michael P, Carr, Aisling S, Reilly, Mary M

“…BackgroundArterial and venous thromboembolic events (TEEs) have been associated with intravenous Ig use, but the risk has been poorly quantified. We aimed to…”
Get full text